Research Analysts Offer Predictions for DAWN Q1 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Wedbush decreased their Q1 2025 EPS estimates for Day One Biopharmaceuticals in a report issued on Monday, April 21st. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.45) for the quarter, down from their prior forecast of ($0.43). Wedbush has a “Outperform” rating and a $32.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share. Wedbush also issued estimates for Day One Biopharmaceuticals’ Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.73) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.20) EPS, FY2028 earnings at ($0.09) EPS and FY2029 earnings at $0.86 EPS.

DAWN has been the topic of several other research reports. The Goldman Sachs Group cut their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th. Bank of America reduced their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. cut their price objective on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Day One Biopharmaceuticals has an average rating of “Buy” and an average target price of $32.29.

Day One Biopharmaceuticals Price Performance

NASDAQ DAWN opened at $7.33 on Wednesday. Day One Biopharmaceuticals has a 1-year low of $6.41 and a 1-year high of $18.07. The firm has a market capitalization of $742.92 million, a P/E ratio of -7.12 and a beta of -1.24. The business’s 50-day simple moving average is $8.62 and its 200-day simple moving average is $11.71.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The company had revenue of $29.21 million during the quarter, compared to analysts’ expectations of $27.11 million.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in shares of Day One Biopharmaceuticals in the 4th quarter worth approximately $27,000. R Squared Ltd acquired a new position in Day One Biopharmaceuticals in the fourth quarter worth $31,000. Pallas Capital Advisors LLC bought a new stake in Day One Biopharmaceuticals during the first quarter valued at $87,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Day One Biopharmaceuticals during the first quarter worth $88,000. Finally, Exchange Traded Concepts LLC lifted its position in shares of Day One Biopharmaceuticals by 19.6% in the 1st quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company’s stock worth $117,000 after buying an additional 2,407 shares during the last quarter. 87.95% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CFO Charles N. York II sold 4,370 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $52,265.20. Following the completion of the sale, the chief financial officer now owns 252,638 shares of the company’s stock, valued at approximately $3,021,550.48. The trade was a 1.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. This trade represents a 10.50 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,064 shares of company stock worth $251,925. 8.40% of the stock is currently owned by corporate insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.